News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
HBAR price rises after Hedera and FedEx partnership, but risks remain
Crypto.News·2026/02/15 07:09
Hotcoin and ENI Accelerate Real-World Web3 Adoption
BlockchainReporter·2026/02/15 07:00
The 20 Altcoins That Attracted the Most Fund Inflows and Experienced Fund Outflows in the Last Week Have Been Revealed
BitcoinSistemi·2026/02/15 06:42
Crypto market rally today: here’s why Pepe Coin, Zcash, Morpho, and Dogecoin are rising
Crypto.News·2026/02/15 06:39
Shiba Inu Loses Key Support, Experts See Steep 77% Drop Ahead
Cryptonewsland·2026/02/15 06:39
Bear Market Survivors: LiquidChain ($LIQUID) and the Case for the Best Altcoin to Buy
Newsbtc·2026/02/15 06:36
Orexn Web3 Launchpad Integrates Support for Sileon’s SEN Launchpool
BlockchainReporter·2026/02/15 06:00
WBTC Whales Manipulated Markets to Make Millions via Flash Loans
BlockBeats·2026/02/15 05:30
Uber enters 7 new European markets in food-delivery push, FT reports
101 finance·2026/02/15 05:27
Analysts See 123% Upside To SoundHound AI, Inc. (SOUN)
Finviz·2026/02/15 04:54
Flash
13:39
BTC current market dominance drops to 51.14%BTC declined, with a trading volume of $28.7 billions in the past 24 hours, a circulating market capitalization of $1.35 trillions, and a market share decrease of 0.49%. Data is for reference only.
13:31
Medtronic Q3 revenue up 8.7% year-on-year, full-year adjusted EPS guidance below expectationsGlonghui, February 17th｜Medical device manufacturer Medtronic announced its fiscal year 2026 third quarter results, with revenue increasing by 8.7% year-on-year to $9.0 billion, exceeding market expectations by $110 million; adjusted earnings per share were $1.36, surpassing market expectations by $0.02. The company reaffirmed its fiscal year 2026 organic revenue growth forecast of approximately 5.5%, and its adjusted earnings per share forecast of $5.62 to $5.66, which is below the market consensus of $6.12.
13:22
Disc Medicine executives noted during a conference call that the policy debate over accelerated approval pathways has spanned multiple government administrations.Recent decisions by regulatory authorities indicate that their assessment of the criteria for accelerated approval is becoming "increasingly stringent."